Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques

Author:

Coppola, Jessica

Parren, Mara

Bastidas, Raiza

Saye, Karen

Malvin, Jacqueline

Jardine, Joseph G

Gilbride, Roxanne M

Ojha, Sohita

Feltham, Shana

Morrow, David

Barber-Axthelm, Aaron

Bochart, Rachele

Fast,Randy

Oswald, Kelli

Shoemaker,Rebecca

Lifson,Jeffrey

Picker, Louis J

Burton, Dennis R

Hansen, Scott G
Author Address

Department of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States., Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States., AIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.,

Abstract:

A vaccine is considered essential for controlling the HIV pandemic and ultimately eradicating AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have shown the ability to protect against the simian counterpart of HIV, SIV, in rhesus macaques. In this study, we provide preliminary evidence that combining these orthogonal antiviral mechanisms can offer increased protection against SIV. Specifically, the replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced by the presence of a passively administered neutralizing antibody at incompletely protective levels. This report encourages studies involving larger cohorts of macaques and alternative methods for administering neutralizing antibodies. Copyright © 2025 Coppola, Parren, Bastidas, Saye, Malvin, Jardine, Gilbride, Ojha, Feltham, Morrow, Barber-Axthelm, Bochart, Fast, Oswald, Shoemaker, Lifson, Picker, Burton and Hansen.

See More

Author Address